Silcura® AD (atopic dermatitis)
First-line therapy is extremely important in the treatment of atopic dermatitis (neurodermatitis, eczema). The tolerability and functionality of the chosen skin care play a key role, therefore. By using the right medicinal skin care to treat mild or moderate eczema, it is often possible to avoid using cortisone or at least reduce its use significantly.
Dry, cracked eczematous skin is particularly susceptible to Staphylococcus aureus infections. In many people, this bacterium already exists on the skin and, as a type of MRSA, it has become a problem in hospitals, where it can lead to infections that are difficult to treat. It also produces bacterial antigens, which perpetuate and exacerbate the atopic eczema. In more than 90% of patients, there is evidence of a high concentration of the bacterium on eczematous skin. The severity of the symptoms correlates with the extent of the colonization.
Silcura® – well-tolerated emulsion with antimicrobial MicroSilver
Silcura® provides a solution in the form of a well-tolerated emulsion with antimicrobial MicroSilver that counteracts Staphylococcus aureus on the epidermis. This allows the degree of skin colonization to be restored to a healthy balance. Constant inflammation often results in intense itching of the reddened, scaly skin. This leads to scratching, which can cause the skin to weep and sometimes also to bleed. An increase in Staphylococcus aureus could be a trigger for the inflammation.
Very high tolerability
Contains MicroSilver as an antimicrobial and anti-inflammatory agent
Effective against Staphylococcus aureus bacteria
Contains ceramide 3 and L-(+)-lactic acid for repairing the skin barrier
Patented formulation technology
Easy to apply as a spray or from a tube
Where is Silcura® available?
Silcura® is currently available on the Latin-American market and, under the brand names PelCare® Silber and Belcura®, in Europe.